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Background: Linezolid is one of the most effective treatments against Gram-positive pathogens. However, linezolid-
resistant/intermediate strains have recently emerged in worldwide. The purpose of this study was to analyse the
prevalence and resistance mechanisms of linezolid-resistant/intermediate staphylococci and enterococci in Shanghai,
China.
Results: Thirty-two linezolid-resistant/intermediate strains, including 14 Staphylococcus capitis, three Staphylococcus
aureus, 14 Enterococcus faecalis and one Enterococcus faecium clinical isolates, were collected in this study which
displayed linezolid MICs of 8 to 512 μg/ml, 8–32 μg/ml, 4–8 μg/ml and 4 μg/ml, respectively. All linezolid-resistant S.
capitis isolates had a novel C2131T mutation and a G2603T mutation in the 23S rRNA region, and some had a C316T
(Arg106Cys) substitution in protein L4 and/or harboured cfr. Linezolid-resistant S. aureus isolates carried a C389G
(Ala130Gly) substitution in protein L3, and/or harboured cfr. The cfr gene was flanked by two copies of the IS256-like
element, with a downstream orf1 gene. Linezolid-resistant/intermediate enterococci lacked major resistance
mechanisms. The semi-quantitative biofilm assay showed that 14 linezolid-resistant E. faecalis isolates produced a
larger biofilm than linezolid-susceptible E. faecalis strains. Transmission electron microscopy showed the cell walls of
linezolid-resistant/intermediate strains were thicker than linezolid-susceptible strains.
Conclusion: Our data indicated that major resistance mechanisms, such as mutations in 23S rRNA and ribosomal
proteins L3 and L4, along with cfr acquisition, played an important role in linezolid resistance. Secondary resistance
mechanisms, such as biofilm formation and cell wall thickness, should also be taken into account.
Keywords: Linezolid resistance, Mutations of 23S rRNA and ribosomal proteins, cfr, Biofilm production, Cell wall thicknessBackground
Gram-positive cocci pose a worldwide threat to human
health. The emergence of antibiotic resistance in Gram-
positive cocci, including methicillin-resistant Staphylococcus
aureus (MRSA), vancomycin-resistant staphylococci (VRS)
and vancomycin-resistant enterococci (VRE), has created a
clinical demand for effective novel therapeutic agents.
Linezolid (LZD), the first member of the oxazolidinone
class of antibiotics, was approved for clinical use in 2000
and has a broad spectrum of activity against a variety of
Gram-positive pathogens. It acts by inhibiting protein syn-
thesis via binding to the peptidyl transferase centre of the* Correspondence: ruth_limin@126.com
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unless otherwise stated.50S ribosomal subunit, and preventing formation of the
fMet-tRNA-30S ribosome-mRNA initiation complex [1].
Because of its unique antimicrobial mechanism, linezolid
has been widely applied in the treatment of clinically-
important Gram-positive bacteria, including aerobic and
anaerobic Gram-positive cocci, aerobic and anaerobic
Gram-positive bacilli, and nocardia and mycobacteria
species. However, linezolid-resistant (LR) staphylococcus
was first reported in peritonitis patients undergoing oral
linezolid treatment during peritoneal dialysis in 2001
[2]. Since then, the occurrence of LR strains has been
reported worldwide [3-5].
The major mechanism of resistance to linezolid is caused
by mutations in the V domain of the 23S rRNA gene, with
a G2576T substitution (Escherichia coli numbering) occur-
ring most frequently. C2104T, G2447T, T2500A, A2503G,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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found in LR strains [6-9]. Another resistance mechanism is
horizontal acquisition of cfr, which encodes a methyltrans-
ferase and modifies adenosine at A2503 in the 23S rRNA.
cfr is usually plasmid-located and confers cross-resistance
to phenicol, lincosamide, oxazolidinone, pleuromutilin and
streptogramin A (known as the PhLOPSA phenotype)
[10,11]. Alterations in the ribosomal proteins L3, L4 and
L22, encoded by rplC, rplD and rplV, respectively, have
also been associated with increased resistance to linezolid
[12-14]. In addition, secondary resistance mechanisms,
such as biofilm formation and cell wall thickening, can
enhance resistance to antibiotics as well [15,16].
As the global emergence of LR isolates has increased
[2-7], LR Gram-positive cocci have also become a problem
in China [8,17-19]. To comprehensively understand the
current prevalence and resistance mechanisms among
LR clinical isolates in China, we analysed 32 linezolid-
resistant/intermediate strains, including 14 Staphylococcus




The collection of the linezolid-resistant/intermediate bac-
terial isolates from patients and the related informa-
tion of patients were approved by the ethics committee
of Huashan Hospital, Shanghai Medical College, Fudan
University and the ethics committee of Renji Hospital,
Shanghai Jiaotong University School of Medicine, Shanghai,
People’s Republic of China. All subjects provided written
informed consent before their inclusion in the study.
Bacterial isolates
Thirty-two non-duplicated linezolid-resistant/intermediate
isolates were collected from patients of two Shanghai
comprehensive teaching hospitals in China from 2009–
2013. One of the hospitals was Huashan Hospital, which is
a tertiary care hospital affiliated with Fudan University,
located in the centre of Shanghai. It is one of the largest
(1300 beds) teaching hospitals in china, handling approxi-
mately 8000 admissions per day. The other was Renji
Hospital, a tertiary care hospital affiliated with Shanghai
Jiaotong University, which is located in the east of Shanghai,
and is also one of the largest (1800 beds) teaching hospitals
in china, handling about 9000 admissions per day. The
studied isolates comprised 14 S. capitis (from Huashan
Hospital), three S. aureus (from Huashan hospital), 14
E. faecalis (12 isolates from Huashan Hospital and two
from Renji Hospital) and one E. faecium (from Huashan
Hospital). Among these 32 isolates, 15, 10, 3, 2, 1 and 1
were recovered from patients with bacteraemia, urinary
tract infection, pneumonia, wound infection, biliary tract
infection and prostate infection, respectively (Table 1).Isolates were identified using a VITEK 2 compact system
(bioMérieux, Marcy l’Etoile, France) and a molecular
method based on analysis of the 16S rRNA gene sequence.
S. aureus RN4220 was used as the recipient strain for
transformation experiments. S. aureus ATCC 29213, E.
faecalis ATCC 29212 (both with linezolid MIC of 2 μg/ml,
American type culture collection, USA), S. capitis HS12-
102 and E. faecium HS13-194 (both with linezolid MIC
of <2 μg/ml, from Huashan Hospital) were included as
linezolid-susceptible (LS) strains. All strains were stored
at −70°C until use and were incubated overnight on blood
agar at 37°C.
Antibiotic susceptibility testing
The antimicrobial agents tested were linezolid, vancomycin,
teicoplanin, oxacillin, cefoxitin, trimethoprim-sulfamethoxazole,
erythromycin, clindamycin, chloramphenicol, tetracycline,
ciprofloxacin, penicillin, ampicillin and high-level gentami-
cin. The MIC of each antimicrobial agent was determined
by the broth microdilution MIC method and interpretation
of MIC results was based on 2013 Clinical and Laboratory
Standards Institute guidelines [20]. S. aureus ATCC 29213
was tested concurrently for quality control.
Multilocus sequence typing (MLST) analysis
S. aureus, E. faecalis and E. faecium were screened using a
previously described method [21-23] to detect the seven
housekeeping genes. For S. aureus, there are carbamate kin-
ase (arcC), shikimate dehydrogenase (aroE), glycerol kinase
(glp), guanylate kinase (gmk), phosphate acetyltransferase
(pta), triosephosphate isomerase (tpi), and acetyl coen-
zyme A acetyltransferase (yqiL). For E. faecalis, there are
glucose-6-phosphate dehydrogenase (gdh), glyceraldehydes-
3-phosphate dehydrogenase (gyd), phosphate ATP binding
cassette transporter (pstS), glucokinase (gki), shikimate-5-
dehydrogenase (aroE), xanthine phosphoribosyltransferase
(xpt), and acetyl-CoA acetyltransferase (yiqL). For E.
faecium, there are adenylate kinase (adk), ATP synthase,
alpha subunit (atpA), d-alanine:d-alanine ligase (ddl),
glyceraldehyde-3-phosphate dehydrogenase (gyd), glucose-
6-phosphate dehydrogenase (gdh), phosphoribosylaminoi-
midazol carboxylase ATPase subunit (purK), and phosphate
ATP-binding cassette transporter (pstS). Each sequence was
submitted to the MLST website (http://www.mlst.net) to
determine the allelic profile and sequence type (ST) of each
isolate [24].
PFGE
PFGE was performed according to a previously described
method [25] with some modifications. The staphylococci
were treated with lysostaphin (Sigma-Aldrich, Saint Louis,
MO, USA) and genomic DNA was prepared in agarose
blocks and then digested with the restriction enzyme SmaI
(NEB, Hitchin, UK). The DNA fragments were separated
Table 1 Clinical characteristics of patients with linezolid-resistant Staphylococcus or Enterococcus infection
Strains Organism Underlying diseases Infection type Ward Prior antibiotic use Outcome
HS09-206 S. capitis Haematencephalon,
Hypertension, Renal
failure
Bacteraemia Intensive care unit (ICU) SCF.AMK.MTZ Discharge







HS10-204 S. capitis Craniocerebral injury, Bacteraemia,
Pneumonia
ICU SXT.VAN Discharge
HS10-24 S. capitis Hip joint surgery, Bacteraemia, Diffuse
peritonitis
ICU TZP.MEN.LZD. LVX.SCF Discharge
HS11-203 S. capitis Bladder surgery, Infective
shock
Bacteraemia ICU MEN.VAN Discharge
HS11-44 S. capitis Subarachnoid
haemorrhage
Bacteraemia ICU LZD Discharge
HS12-49 S. capitis Craniocerebral injury, Bacteraemia,
Pneumonia
ICU VAN.SCF Discharge
HS12-201 S. capitis Ventricular fibrillation,
Epilepsy
Bacteraemia ICU MEN.SCF.AMK. TZP Discharge





HS12-53 S. capitis Craniocerebral injury Bacteraemia Department of
Cerebral Surgery
MEN.AMK.SAM.VAN Discharge




ICU IPM.FOF.MEN. SCF.DOX Discharge
HS12-58 S. capitis Subarachnoid
haemorrhage
Bacteraemia ICU CXM.SCF Discharge
HS13-60 S. capitis Brain tumour operation,
Respiratory failure
Bacteraemia ICU MEN.LZD.SCF. DOX Discharge
HS13-207 S. capitis Subarachnoid
haemorrhage
Bacteraemia ICU IPM.LZD.VAN. FEP.TEC.CAZ.
LVX.AMK
Discharge
HS09-205 S. aureus COPD, Coronary disease Pneumonia General ward SCF Discharge
HS11-202 S. aureus Hematencephalon Pneumonia ICU SCF Discharge
HS12-56 S. aureus Craniocerebral injury Pneumonia ICU VAN.SCF Discharge
HS10-311 E. faecalis Urinary tract infection Urinary infection Department of
Urology (outpatient)
N/day Infection cleared







HS11-305 E. faecalis Urinary tract infection Urinary infection Department of
Urology (outpatient)
N/D Infection cleared





HS12-309 E. faecalis Urinary tract infection Urinary infection Department of
Urology (outpatient)
N/D Infection cleared
HS12-308 E. faecalis Urinary tract infection Urinary infection Department of
Urology (outpatient)
N/D Infection cleared
HS12-310 E. faecalis Femoral fracture Wound infection Department of
Orthopaedics
MEN Discharge
HS13-301 E. faecalis Urinary tract infection Urinary infection Department of
Urology (outpatient)
N/D Infection cleared
HS13-302 E. faecalis Scrofula Biliary tract infection Department of
Infectious Disease
MXF.SCF.IHY.PYR. Discharge
HS13-303 E. faecalis Drug fever Urinary infection Department of
Infectious Disease
AZM Discharge
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Table 1 Clinical characteristics of patients with linezolid-resistant Staphylococcus or Enterococcus infection (Continued)
RJ13-314 E. faecalis Juvenile arthritis Urinary infection Department of Urology
(outpatient)
N/D Infection cleared
RJ13-315 E. faecalis Chronic prostatitis Prostate infection Department of
Urology (outpatient)
N/D Infection cleared
HS13-312 E. faecalis Psoriasis Wound infection Department of
Dermatology
Not used Discharge
HS13-313 E. faecalis Urinary tract infection Urinary infection Department of
Urology (outpatient)
N/D Infection cleared
HS11-306 E. faecium Lithangiuria Urinary infection Department of
Urology
TZP.SAM.VAN.LVX.CXM Discharge
HS, isolate from Huashan Hospital; RJ, isolate from Renji Hospital; COPD, chronic obstructive pulmonary disease; SCF, cefoperazone/sulbactam; AMK, amikacin;
MTZ, metronidazole; MEM, meropenem; LZD, linezolid; DOX, doxycycline; SXT, sulfamethoxazole/trimethoprim; VAN, vancomycin; TZP, piperacillin/tazobactam;
LVX, levofloxacin; IPM, imipenem; FEP, cefepime; TEC, teicoplanin; CAZ, ceftazidime; SAM, ampicillin/sulbactam; FOF, fosfomycin; CXM, cefuroxime; MXF,
moxifloxacin; IHY, isonicotinyl hydrazide; PYR, pyrazinamide; AZM, Azithromycin. N/D, not determined.
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USA) for 20 h at 6 V/cm and 14°C, with a pulse angle of
120° and pulse times from 5–25 s. PFGE banding patterns
were analysed visually.
Molecular detection of resistance genes and mutations
Isolates were screened for the presence of cfr and muta-
tions in the 23S rRNA and the L3, L4 and L22 ribosomal
proteins by PCR and DNA sequencing, as previously
described [26,27]. Amplicons were sequenced on both
strands and were compared with those from S. aureus
ATCC 29213, E. faecalis ATCC 29212, LS S. capitis and
LS E. faecium, obtained from Shanghai Huashan Hospital
during the study period, using the Lasergene software
package (DNAStar; Madison, WI, USA).
Gene dosage
Gene dosage was determined according to a previously
described method [28,29] with some modifications. Iso-
lates of LR S. capitis containing mutations in the central
loop of the 23S rRNA gene were amplified using primers
based on the S. capitis 23S rRNA gene (primer F, 5′-
AAGGCGTAACGATTTGGG-3′; primer R, 5′-CAGCA
CTTATCCCGTCCA-3′; expected PCR product size:
720 bp). Thermal cycler conditions were 94°C for 5 min,
followed by 35 cycles of 94°C (30 s), 55°C (30 s) and 72°C
(30 s), with a final extension at 72°C (7 min). The DNA
concentration of PCR amplicons was normalized to 0.3
pmol prior to cloning. Then, the amplification products
were ligated to plasmid pMD-18 T (Takara Biotechnology,
Dalian, China) and transformed into E. coli DH5α cells
(Sangon Biotech, Shanghai, China). Each LR S. capitis was
cloned and 30 clones from each strain were sequenced.
Plasmid analysis and cfr location
Plasmid DNA was extracted from all cfr-carrying isolates
using a Plasmid DNA Midi Kit (QIAGEN, Hilden,
Germany) and separated on 1% (w/v) agarose gel. The
migration distances of DNA bands were measured directlyfrom gel photographs in relation to the reference plasmids
in E. coli V517 (sizes, 54, 5.6, 5.1, 3.9, 3.0, 2.7, and 2.1 kb)
marker. Plasmid DNA bands were transferred onto a nylon
membrane by Southern blotting. A cfr-specific labelled
probe (primer F, 5′-GAAGCTCTAGCCAACCGTCA-3′;
primer R, 5′-TCTACCTGCCCTTCGTTTGC3′; expected
PCR product size: ~600 bp) was generated using a non-
radioactive DIG High Prime DNA Labelling and Detection
Kit (Roche Applied Sciences, Mannheim, Germany)
according to the manufacturer’s instructions, and was
hybridised to the membrane. To determine the genetic
environment of cfr, the partial plasmid DNA sequence of
all cfr-carrying isolates was determined using the fol-
lowing primers, designed based on the sequence of pSS-01
(GenBank accession no. JQ041372): 1 F 5′- CACTTCCTT
TATTATTTTTC-3′; 1R 5′- CGACTGAATCAAGAAGT
ACG-3′; 2 F 5′-TGAACCATAACCTTTGTC-3′, 2R 5′-
TGTTTCTAGCCTGACTGA-3′; 3 F 5′-ACTCGATGG
TCCTCACGG-3′, 3R 5′-TCAGGCTCATTATTACTTC-3′;
4 F 5′-TTACCACTAGAGCAAATT′, 4R 5′-GACCAC
AAGCAGCGYCAA-3′; 5 F 5′-AATGGACTACTGGG
TGGA-3′, 5R 5′-ATGATTCAGAAAGCAGAT-3′; 6 F
5′-CTTTCCGAATGGACTAAT-3′, 6R 5′-TGAGCGC
AGCTTTACGAC-3′ (PCR product sizes: 1000 ~ 2500 bp).
Amplification products from the ten cfr-carrying plasmids
were sequenced on both strands and were compared with
plasmid pSS-01 using the Lasergene software package
(DNAStar; Madison, WI, USA). In addition, the purified
plasmids extracted from each of the ten original strains
were electrotransformed (2kv, 25 μF, 1000Ω) into the S.
aureus recipient strain RN4220. Transformants were incu-
bated in fresh tryptic soy broth (TSB; Oxoid, Basingstoke,
UK) at 37°C with shaking at 200 rpm for 1 h and then
were selected by incubation for 24 h at 37°C on TSB
agar supplemented with 6 μg/ml linezolid. The linezolid
MICs of transformants were measured by the broth
microdilution method. Plasmid DNA was extracted
from all the transformants and separated on 1% agarose
gel. Southern hybridisation was then used to confirm
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previously [17].
Detection of biofilm production
All LR strains were divided into four groups by species
(S. capitis, S. aureus, E. faecalis and E. faecium). S. capitis
group contained 14 LR isolates and 14 LS isolates. S. aureus
group contained 3 LR isolates and 15 LS isolates. E. faecalis
group contained 14 LR isolates and 14 LS isolates. E.
faecium group contained 1 LR isolate and 15 LS isolates.
A semi-quantitative biofilm assay was conducted using
flat-bottomed, tissue culture-treated, 96-well assay plates
(Costar 3599; California, USA). Four wells in each assay
plate contained untreated cultures, which served as nega-
tive controls. Bacteria were prepared by making a 1:100
dilution of an overnight culture grown in TSB contain-
ing 5 g/L glucose. Assay plates were inoculated with
200 μL of culture per well (OD600 = 0.01) and were in-
cubated at 37°C for 24 h. The medium were removed
from assay plates. Then assay plates were washed four
times with PBS. Biofilms were fixed by Bouin’s fixation
for at least 1 h then assay plates were washed four
times with PBS. Following crystal violet staining, the
biofilms were measured using a Synergy H1 Hybrid Multi-
Mode Microplate Reader (Biotek, Vermont, USA) at OD570.
Transmission electron microscopy (TEM)
Isolates for TEM were grown from a single colony in
10 mL of liquid brain-heart infusion (BHI) medium with
0.5% (w/v) beef extract. Four groups were studied. The
S. capitis group contained strains HS12-102 (LS S. capitis
strain HS12-55), HS09-17 (MIC 16 μg/ml), HS09-17 +
LZD (strain HS09-17 grown in BHI broth containing
4 μg/ml linezolid), HS12-55 (MIC >256 μg/ml) and
HS12-55 + LZD (strain HS12-55 grown in BHI broth con-
taining 32 μg/ml linezolid). The S. aureus group contained
S. aureus ATCC29213 (LS S. aureus), HS11-202 (MIC
16 μg/ml) and HS11-202 + LZD (strain HS11-202 grown
in BHI broth containing 2 μg/ml linezolid). The E. faecalis
group contained E. faecalis ATCC29212 (LS E. faecalis),
HS11-304 (MIC 4 μg/ml), HS12-309 (MIC 8 μg/ml) and
HS12-309 + LZD (strain HS12-309 grown in BHI broth
containing 2 μg/ml linezolid). Finally, the E. faecium group
contained strains HS13-194 (LS E. faecium) and HS11-306
(MIC 4 μg/ml). The cells were grown at 37°C with shaking
at 200 rpm for approximately 4–5 h to mid-exponential
phase (OD600 ~ 0.7–0.8). An 8-mL volume of each cul-
ture was pelleted by centrifugation at 4000 g for 15 min
and suspended in 1 mL of 2.5% (v/v) glutaraldehyde in
0.1 M phosphate buffer, and stored at 4°C for at least 2 h.
The cells were then post-fixed with 1% (w/v) osmium
tetroxide in the same buffer. Following dehydration, cells
were infiltrated with and embedded in Eponate 12 resin
for 24 h. Ultrathin sections were cut at 70 nm, stainedwith uranyl acetate and lead citrate, and then examined on
a JEM-1230 80 kV TEM (JEOL, Tokyo, JAPAN) equipped
with a Gatan Orius SC200W camera. Images were cap-
tured at 30,000× magnification and measurements were
made using ImageJ software [30]. Thirty cell walls were
measured per sample, and means and standard deviations
were calculated in Excel (Microsoft, San Francisco, USA).
Results
Incidence of linezolid resistance
From 2009–2013, 3446 Staphylococcus and 1713 Entero-
coccus non-duplicated isolates were tested for susceptibil-
ity to linezolid. The incidence of linezolid resistance in
our study was 1.18% of coagulase-negative staphylococci
(CONS) (14/1188 isolates), 0.13% of S. aureus (3/2258 iso-
lates), 1.72% of E. faecalis (14/812 isolates) and 0.11%
of E. faecium (1/877 isolates) isolates.
Antimicrobial susceptibility testing
The susceptibility profiles of 14 S. capitis isolates, three
S. aureus isolates and 14 E. faecalis isolates were similar
(Table 2). The S. capitis isolates showed various levels of
linezolid resistance, with MIC values of 8–512 μg/ml.
The S. aureus isolates were resistant to linezolid, with
MIC values of 8–32 μg/ml. Other than S. aureus HS09-205,
all staphylococcal strains were methicillin-resistant and
exhibited high-level resistance to most of the antibiotics
tested, except for vancomycin, teicoplanin and tetracyc-
line. Moreover, 17 staphylococcal isolates showed different
levels of trimethoprim-sulfamethoxazole susceptibility
data, with MIC values of 0.12/2.37–8/152 μg/ml. The fif-
teen enterococcal isolates demonstrated either linezolid-
intermediate (LI) or low-level linezolid resistance (MICs
4–8 μg/ml). These strains were resistant to erythromycin,
chloramphenicol, ciprofloxacin and tetracycline (isolate
HS11-307 was susceptible to tetracycline, with a MIC
of 1 μg/ml), but susceptible to vancomycin (MICs, 0.5–
2 μg/ml), teicoplanin (MICs, 0.12–0.25 μg/ml), penicillin
(MICs, 0.5–4 μg/ml) and ampicillin (MICs, <0.5–4 μg/ml).
Eight enterococcal isolates (HS11-304, HS12-309, HS12-
308, HS12-310, HS13-301, HS13-303, RJ13-314 and HS11-
306) were not high-level resistant to gentamicin, whereas
the remaining strains were resistant.
MLST and molecular typing
All of the isolates, except for those from S. capitis, were
typed by MLST. The STs of the three S. aureus isolates
were ST5, ST88 and ST239. The 14 E. faecalis isolates
were classified into eight STs: two isolates each belonged
to ST4, ST16, ST69, and ST476, while three were ST480
and three others belonged to different STs. The E. faecium
isolate belonged to ST650. PFGE analysis showed that
nine S. capitis isolates (HS11-203, HS11-44, HS12-49,
HS12-201, HS12-51, HS12-53, HS2-55, HS12-58, HS13-60)
Table 2 Antimicrobial susceptibility profiles and genetic resistance markers of linezolid-resistant Staphylococcus and Enterococcus isolates
Strain ID Source ST MIC (μg/ml) Genetic resistance markers
LZD VAN TEC OXA FOX ERY CLI CHL TET CIP PEN AMP GNH SXT 23S rRNA mutation
(percentage of clones
with mutation)
cfr L3 L4 L22
S. capitis
HS09-206 blood N/D 8 1 0.25 >256 R >256 >256 32 4 64 64 N/D N/D 2/38 C2131T (43.3%) - - - -
G2603T (70.0%)
HS09-17 blood N/D 16 1 0.25 256 R >256 256 32 4 64 32 N/D N/D 2/38 C2131T (46.7%) - - - -
G2603T (83.3%)
HS10-204 blood N/D 32 1 0.5 >256 R >256 >256 128 4 64 64 N/D N/D 4/76 C2131T (36.7%) - - - -
G2603T (66.7%)
HS10-24 blood N/D 64 1 0.25 256 R >256 >256 32 4 64 32 N/D N/D 8/152 C2131T (53.3%) - - - -
G2603T (80.0%)
HS11-203 blood N/D 256 1 0.25 >256 R >256 >256 128 4 64 64 N/D N/D 2/38 C2131T (60.0%) + - - -
G2603T (80.0%)
HS11-44 blood N/D 256 1 0.25 >256 R >256 256 64 4 64 32 N/D N/D 2/38 C2131T (53.3%) + - - -
G2603T (80.0%)
HS12-49 blood N/D 256 1 0.5 >256 R >256 >256 128 4 64 32 N/D N/D 4/76 C2131T (70.0%) + - - -
G2603T (70.0%)
HS12-201 blood N/D 512 1 0.25 >256 R >256 >256 128 4 64 64 N/D N/D 4/76 C2131T (60.0%) + - C316T(Arg106 Cys) -
G2603T (100%)
HS12-51 blood N/D 128 1 0.5 256 R >256 256 32 4 64 64 N/D N/D 2/38 C2131T (36.7%) + - - -
G2603T (63.3%)
HS12-53 blood N/D 512 1 0.25 >256 R >256 256 128 4 64 32 N/D N/D 8/152 C2131T (60.0%) + - - -
G2603T (80.0%)
HS12-55 blood N/D 512 1 0.25 >256 R >256 >256 128 4 64 32 N/D N/D 4/76 C2131T (50.0%) + - C316T(Arg106 Cys) -
G2603T (86.7%)
HS12-58 blood N/D 512 1 0.25 >256 R >256 >256 64 2 32 8 N/D N/D 4/76 C2131T (60.0%)G2603T
(100%)
+ - - -
HS13-60 blood N/D 256 1 0.5 >256 R >256 >256 64 4 64 64 N/D N/D 4/76 C2131T (60.0%) + - - -
G2603T (76.7%)
HS13-207 blood N/D 32 1 0.25 >256 R >256 >256 32 4 64 32 N/D N/D 8/152 C2131T (83.3%) - - - -
G2603T (100%)
S. aureus


















Table 2 Antimicrobial susceptibility profiles and genetic resistance markers of linezolid-resistant Staphylococcus and Enterococcus isolates (Continued)
HS11-202 sputum 239 16 1 1 >256 R >256 >256 32 4 128 128 N/D N/D 0.25/4.75 - - C389G(Ala130Gly) - -
HS12-56 sputum 5 32 1 1 >256 R >256 >256 32 8 128 8 N/D N/D 0.12/2.37 - + - - -
E. faecalis
HS10-311 urine 16 4 1 0.12 N/D N/D >256 N/D 32 128 64 2 <0.5 R N/D - - - - -
HS11-304 blood 16 4 1 0.5 N/D N/D >256 N/D 32 64 16 2 <0.5 S N/D - - - - -
HS11-305 urine 476 4 1 0.25 N/D N/D >256 N/D 32 128 16 4 <0.5 R N/D - - - - -
HS11-307 urine 4 4 2 0.12 N/D N/D >256 N/D 32 1 64 0.5 <0.5 R N/D - - - - -
HS12-309 urine 69 8 2 0.12 N/D N/D >256 N/D 32 64 64 0.5 <0.5 S N/D - - - - -
HS12-308 urine 480 8 1 0.25 N/D N/D >256 N/D 32 32 64 4 <0.5 S N/D - - - - -
HS12-310 wound 300 8 1 0.25 N/D N/D >256 N/D 32 64 64 2 4 S N/D - - - - -
HS13-301 urine 476 8 1 0.25 N/D N/D >256 N/D 64 128 64 2 <0.5 S N/D - - - - -
HS13-302 bile 27 8 0.5 0.125 N/D N/D >256 N/D 32 128 64 2 <0.5 R N/D - - - - -
HS13-303 urine 480 8 1 0.125 N/D N/D >256 N/D 32 64 16 0.5 <0.5 S N/D - - - - -
RJ13 -314 urine 69 8 1 0.12 N/D N/D >256 N/D 32 64 16 1 <0.5 S N/D - - - - -
RJ13 -315 urine 4 8 1 0.25 N/D N/D >256 N/D 32 128 64 2 <0.5 R N/D - - - - -
HS13-312 wound 37 4 1 0.25 N/D N/D >256 N/D 32 64 16 4 4 R N/D - - - - -
HS13-313 urine 480 4 1 0.25 N/D N/D >256 N/D 64 128 64 2 <0.5 R N/D - - - - -
E. faecium
HS11-306 urine 650 4 2 0.25 N/D N/D >256 N/D 32 128 16 4 2 S N/D - - - - -
ST, sequence typing; R, resistant; S, susceptible; LZD, linezolid; VAN, vancomycin; OXA, oxacillin; FOX, cefoxitin; ERY, erythromycin; CLI, clindamycin; CHL, chloramphenicol; TET, tetracycline; CIP, ciprofloxacin; PEN,
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http://www.biomedcentral.com/1471-2180/14/292exhibited identical band pattern, and four other isolates
also shared the same band pattern (HS09-206, HS09-17,
HS10-204, HS10-24). HS13-207 showed a unique band
pattern (Figure 1). In addition, E. faecalis isolates from the
same ST also exhibited different band patterns.
Resistance genes and mutations
A novel C2131T mutation and a previously reported
G2603T mutation, both in domain V of the 23S rRNA
gene, were identified in all S. capitis isolates (Table 2). All
S. capitis isolates, except HS09-206, HS09-17, HS10-204,
HS10-24 and HS13-207, were positive for cfr. Further-
more, S. capitis HS12-201 and HS12-55 had C316T
(Arg106Cys) mutations in ribosomal protein L4, but no
mutations were detected in ribosomal proteins L3 or L22
in any isolates. Among S. aureus isolates, only HS12-56
was positive for cfr. S. aureus HS11-202 had a C389G
(Ala130Gly) mutation in ribosomal protein L3, but pro-
teins L4 and L22 were wild-type. No mutation was identi-
fied in any of the studied genes in the E. faecalis and
E. faecium isolates, nor was cfr detected.
Gene dosage
Gene dosage tests were performed on fourteen LR S.
capitis isolates that contained mutations in domain V of
the 23S rRNA gene. Isolates with different linezolid re-
sistance levels displayed diverse C2131T and G2603T mu-
tation rates (Table 2). The relationship between linezolid
resistance levels and the percentage of mutated 23S rRNA
genes in S. capitis is shown in Figure 2. Clones derived
from S. capitis (linezolid MIC 8–64 μg/ml) had mutationFigure 1 PFGE of SmaI-digested chromosomal DNA of linezolid-resistan
HS10-24; 44, HS11-44; 49, HS12-49; 51, HS12-51; 53, HS12-53; 55, HS12-55; 58, H
HS09-206; 207, HS13-207. Lane 302–311, fourteen isolates of LR E. faecalis. 302
311, HS10-311; 307, HS11-307; 315, RJ13-315; 309, HS12-309; 314, RJ13-314; 30
Lane 56–205, three isolates of LR S. aureus. 56, HS12-56; 202, HS11-202; 205, Hrates of 36.7–83.3% (C2131T) and 63.3–100% (G2603T),
and those derived from S. capitis (linezolid MIC 256–
512 μg/ml) had mutation rates of 50.0–70.0% (C2131T)
and 70.0–100% (G2603T).Genetic environment of cfr in plasmids
Southern hybridisation indicated that cfr resided on plas-
mids of similar sizes (ca. 54 kb) in all ten cfr-positive iso-
lates (Figure 3). The cfr-carrying plasmids were extracted
from the isolates and transformed into S. aureus RN4220.
Plasmids were then extracted from all the transformants
and were confirmed by Southern hybridisation (data not
shown). The linezolid MICs of ten transformants were
32 μg/ml. The genetic environment surrounding cfr in
pHS (plasmid from Huashan Hospital) was shown to be
identical in all ten cfr-carrying plasmids and showed
99% identity to the corresponding region of plasmid
pSS-01 (GenBank accession no. JQ041372, Figure 4). The
cfr gene was located downstream of aminoglycoside resist-
ance gene aacA-aphD and was flanked by two copies of
the IS256-like element, with a downstream orf1 gene.Biofilm production
The semi-quantitative biofilm assay showed that the mean
biofilm production in LR E. faecalis strains was signifi-
cantly higher than that in LS E. faecalis strains (P < 0.0001,
one-way ANOVA), whereas there were no significant dif-
ferences between LR and LS isolates from the other three
species (Figure 5).t isolates. Lane 17–207, fourteen isolates of LR S. capitis. 17, HS09-17; 24,
S12-58; 60, HS13-60; 201, HS12-201; 203, HS11-203; 204, HS10-204; 206,
, HS13-302; 310, HS12-310; 312, HS13-312; 301, HS13-301; 305, HS11-305;
3, HS13-303; 308, HS12-308; 313, HS13-313; 304, HS11-304; 311, HS10-311.
S09-205.
Figure 2 Mutations in the 23S rRNA gene and linezolid resistance levels in LR S. capitis isolates. A. The percentages of clones with C2131T and
G2603T mutations. B. The percentage of clones with C2131T mutations in isolates with various linezolid resistance levels. C. The percentage of clones
with G2603T mutations in isolates with various linezolid resistance levels. Error bars represent the mean ± SEM.
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TEM showed differences in cell wall thickness between
LS, LI and LR strains grown with and without linezolid
(Figure 6, Table 3). The overall cell diameter had not
significant difference between any of the strains of each
species (data not shown), but the cell walls of LI and LR
strains were thicker than those of LS strains (P < 0.0001,
two-tailed t-test),except for LI E. faecium HS11-306. Fur-
thermore, the cell wall of LR strains grown with linezolid
were thicker than that without linezolid (P < 0.0001, two-
tailed t-test), except for LR E. faecalis HS12-309 (P ≤ 0.001,
two-tailed t-test) (Figure 7).
Discussion
The prevalence of MRSA, VRS and VRE strains has
presented a new challenge in antimicrobial medication.Figure 3 Analysis of plasmids in cfr-positive S. capitis isolates. Plasmids
hybridisation of S. capitis isolates with a cfr probe. B. M, E. coli V517 marker; 20
HS12-53; 55, HS12-55; 58, HS12-58; 60, HS13-60; 56, HS12-56.Linezolid is one of the few treatment options that is highly
active against Gram-positive pathogens. However, LR strains
have been increasingly reported in worldwide [2-7,9-14] and
now have also emerged in China [8,17-19]. Although
the incidence of linezolid resistance among Gram-positive
organisms remains low, the emergence of LR strains is still
of great concern.
Surveillance data in our study suggested that all the LR
S. capitis were recovered from bacteraemia patients,
whereas LR S. aureus (LRSA) came from respiratory tract
specimens. Linezolid-resistant/intermediate enterococci were
collected from blood, urine, wound, bile and prostatic
fluid. All of the patients infected with LR staphylococci
were critically ill, which is consistent with findings from
previous studies [8,17-19]. A study in Spain [31] described
that LR strains emerged after patients received threeof ca.54 kb were detected in all ten cfr-positive isolates. A. Southern
3, HS11-203; 44, HS11-44; 49, HS12-49; 201, HS12-201; 51, HS12-51; 53,
Figure 4 Schematic representation of the genetic environment of cfr in pHS and pSS-01. The arrows indicate the positions and directions
of the transcription of the genes. The regions of homology between pHS and pSS-01 (GenBank accession no. JQ041372) are indicated by dashed
lines and grey shading. Δ indicates a truncated gene.
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http://www.biomedcentral.com/1471-2180/14/292courses of linezolid for 600 mg every 12 h for 14 days.
Interestingly, as shown in Table 1, only seven hospita-
lised patients (HS09-17, HS10-24, HS11-44, HS12-51,
HS13-60, HS13-207 and HS11-307) in our study had
received linezolid therapy (range 13–40 days) prior to
the appearance of LR strains. The remaining patients,
other than outpatients whose antibiotic drug histories
were not determined, had not been exposed to linezolid.
So, except for linezolid exposure, if there were other fac-
tors involved worth considering.
Nowadays, linezolid susceptibility of Gram-positive clin-
ical isolates is mainly monitored through two surveillance
programmes, the Zyvox Annual Appraisal of Potency and
Spectrum (ZAAPS) Program in Europe and the Linezolid
Experience and Accurate Determination of Resistance
(LEADER) Program in USA. In 2014, the ZAAPS ProgramFigure 5 Semi-quantitative biofilm analysis of S. capitis, S.
aureus, E. faecalis, E. faecium groups. LS strains were used as
controls. Comparisons are vs. LS E. faecalis strains for LR E. faecalis
strains. ***P < 0.0001 (one-way ANOVA).analysed the linezolid activity of 7972 g-positive clinical
isolates collected over 9 years (2004–2012) from 73 med-
ical centres in 33 countries on five continents [32]. Data
showed that 0.11% of CoNS (8/6909 isolates), 0.02% of
S. aureus (4/25148 isolates), 0.92% of E. faecalis (4/434
isolates) and 0.03% of E. faecium (1/333 isolates) isolates
were resistant to linezolid. Gu et al. [33] summarized the
linezolid susceptibility profile of staphylococci from the
LEADER Program over 7 years (2004–2010). Data showed
that 1.4% of CoNS (73/5202 isolates) and 0.05% of S.
aureus (13/23077 isolates) isolates were resistant to li-
nezolid. Our data showed that the incidence of LR strains
in China was higher than that of the two surveillance pro-
grams, except for LRCoNS which was similar to that
of the LEADER program. In particular, the incidence of
LRCoNS in China was nine times higher than that of
LRSA, and the incidence of LR E. faecalis was 15 times
higher than that of LR E. faecium, suggesting that ongoing
surveillance is necessary.
Recently, multifocal outbreaks of LR staphylococci have
been reported, including S. epidermidis (France, Spain,
Mexico, Italy, Brazil, China), S. cohnii (Mexico, China),
S. haemolyticus (Mexico, Brazil, China), S. sciuri (China),
S. capitis (Greece, China), S. hominis (Brazil), S. lugdenesis
(Brazil) and S. aureus (Italy, Hong Kong, Brazil), and
linezolid-resistant/intermediate enterococci, including E. fae-
calis (Poland, Ireland, China, Taiwan), E. faecium (Germany,
Ireland, China) and E. avium (Poland) [8,18,19,32,34].
In our study, we detected multiple LR S. capitis, S. aureus,
E. faecalis and E. faecium isolates. Notably, the clinically-
derived LRSA isolates characterised in our investigation
are the first to be reported in China. Previous studies
[8,18,19] described that most of LRCoNS in China exhib-
ited high-level resistance (MIC 256 μg/ml), with very
few low- and medium-level LR isolates, whereas in other
countries [32,34], low to medium-level LRCoNS (8–
32 μg/ml) were more common, with a lack of high-level
LRCoNS strains. In contrast, the 14 LRCoNS isolates in
our study exhibited a wide range of linezolid resistance
levels, with MICs from 8 to 512 μg/ml. Three LRSA
Figure 6 (See legend on next page.)
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Figure 6 Transmission electron micrographs (TEM) showing cell wall thickness in bacterial isolates. TEM images show LS S. capitis HS12-102
(A), LR S. capitis HS09-17 (MIC 16 μg/ml) grown without (B) and with (C) 4 μg/ml linezolid, LR S. capitis HS12-55 (MIC >256 μg/ml) grown without
(D) and with (E) 32 μg/ml linezolid, wild-type ATCC29213 S. aureus (F), LR S. aureus HS11-202 (MIC 16 μg/ml) grown without (G) and with (H) 2 μg/ml
linezolid, wild-type ATCC29212 E. faecalis (I), LI E. faecalis HS11-304 (MIC 4 μg/ml) grown without linezolid (J), LR E. faecalis HS12-309 (MIC 8 μg/ml)
grown without (K) and with (L) 2 μg/ml linezolid, LS E. faecium HS13-194 (M), LI E. faecium HS11-306 (MIC 4 μg/ml) grown without linezolid (N). Cell
wall thicknesses are given in Table 3. Scale bars indicate 200 nm.
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http://www.biomedcentral.com/1471-2180/14/292isolates exhibited linezolid resistance (MIC 8–32 μg/
ml), which were higher than LRSA isolates from Italy,
Hong Kong and Brazil (MIC 4–8 μg/ml). Thereinto,
two of the LRSA isolates were methicillin-resistant
and multidrug-resistant, whereas HS09-205 LRSA was
methicillin-susceptible. Moreover, low-level resistance in
linezolid-resistant/intermediate enterococci (MIC 4–8 μg/
ml) was similar to previous studies [8,18,19,32,34]. MLST
and PFGE results showed that LR S. capitis, LR S. aureus,
E. faecalis and E. faecium were polyclonal, suggesting
diverse STs were all vulnerable to linezolid exposure.
Known mechanisms of linezolid resistance in Gram-
positive cocci include mutations in the 23S rRNA gene,
acquisition of cfr and mutations of ribosomal proteins
L3, L4 and L22. The novel mutation C2131T and the
previously-described mutation G2603T in the V domain
of the 23S rRNA were identified in all 14 LR S. capitis
clones. Although G2603T was first reported in 2009 [9],
this is the first report of this mutation in China. The novel
mutation C2131T, whether it plays a role in linezolid
resistance is uncertain and needs a further confirmation.
But this revelation may provide new information for inves-
tigating the mechanism of linezolid resistance caused by
mutations in the V domain of 23S rRNA gene. Because
staphylococci possess five or six copies of the 23S rRNATable 3 Cell wall thickness measured by TEM
Species Strains Cell wall thicknessa
S. capitis HS12-102 30.76 ± 4.10
S. capitis HS09-17 40.12 ± 6.04
S. capitis HS09-17 + 4 μg/ml linezolid 57.54 ± 7.75
S. capitis HS12-55 41.13 ± 6.22
S. capitis HS12-55 + 32 μg/ml linezolid 50.52 ± 7.78
S. aureus ATCC 29213 25.69 ± 2.17
S. aureus HS11-202 31.74 ± 5.73
S. aureus HS11-202 + 2 μg/ml linezolid 43.67 ± 6.30
E. faecalis ATCC 29212 31.01 ± 5.57
E. faecalis HS11-304 40.96 ± 7.41
E. faecalis HS12-309 40.44 ± 5.38
E. faecalis HS12-309 + 2 μg/ml linezolid 46.14 ± 7.55
E. faecium HS13-194 32.42 ± 4.60
E. faecium HS11-306 34.79 ± 5.38
ameasurements (in nm) are means ± standard deviations from 30 cells per
sample.gene, linezolid resistance caused by 23S rRNA mutations
develop slowly. Besier et al. indicated that accumulation of
single point mutations might be associated with gradually-
increasing levels of resistance, in a mechanism known as
“gene dosage” [28]. To gain insight into the relationship
between gene dosage and 23S rRNA mutations, we exam-
ined the proportion of cloned PCR products with muta-
tions. Our data showed that the percentage of clones
with G2603T mutation was significantly higher than that
with the C2131T mutation. Independent of other resistance
mechanisms, various levels of the 23S rRNA muta-
tions mediated low- to medium-level linezolid resistance
(HS09-206, HS09-17, HS10-204, HS10-24, HS13-207;
MICs: 8–64 μg/ml). Moreover, the synergistic action of
mutations in the 23S rRNA gene and ribosomal proteins
L3 and L4, as well as acquisition of cfr gene mediated
high-level linezolid resistance (MICs: 128–512 μg/ml).
However, the complicated background of resistance mech-
anisms involved and the biological characteristics of the
clinical bacteria overlaid the relationship between gene
dosage and linezolid resistance levels.
The cfr gene is often located on transferable plasmid
and is thus considered to promote horizontal spread of
linezolid resistance. In our study, 10 LR staphylococcal
isolates (nine S. capitis and one S. aureus) harboured cfr
gene and all the S. aureus RN4220 transformants showed
that cfr-carrying pHS mediate medium-level linezolid
resistance (MIC 32 μg/ml). Wang et al. had indicated
the two copies of IS256-like elements played an import-
ant role in the dissemination of cfr in animal isolates
[17]. Subsequently, similar structures were found in LR
S. capitis from Zhejiang [18], LR S. cohnii from Beijing
[19], and now LR S. capitis and LR S. aureus from
Shanghai in the current study. Notably, the pHS with
cfr flanked by IS256-like elements is the first to be reported
in a LRSA strain (HS12-56) in this study. Moreover, com-
pared with plasmid S. capitis MHZ (GenBank accession
no. JX232067) from Zhejiang [18], S. capitis pHS possessed
additional upstream aminoglycoside resistance gene aacA-
aphD. Considering the first cfr-positive LR S. capitis strain
was detected in 2011 and HS12-56 LRSA which carried
the same plasmid emerged in 2012, it suggested that
the pHS was most probably transferred from LRCoNS
to LRSA. This finding presented significant concerns
about the possibility of cfr-positive LRCoNS acting as
reservoirs for linezolid resistance. Based on the information
Figure 7 Comparison between bacterial cell wall thickness in LS, LR and LI isolates. There are S. capitis (A), S. aureus (B), E. faecalis (C) and
E. faecium (D) isolates. 102, HS12-102; 17, HS09-17; 17 + LZD, HS09-17 grown with 4 μg/ml linezolid; 55, HS12-55; 55 + LZD, HS12-55 grown with
32 μg/ml linezolid; ATCC29213, ATCC29213 LS S. aureus; 202, HS11-202; 202 + LZD, HS11-202 grown with 2 μg/ml linezolid; ATCC29212, ATCC29212 LS
E. faecalis; 304, HS11-304; 309, HS12-309; 309 + LZD, HS12-309 grown with 2 μg/ml linezolid; 194, HS13-194; 306, HS11-306 (MIC 4 μg/ml). LS reference
strains HS12-102 (S. capitis), ATCC29213 (S. aureus), ATCC29212 (E. faecalis) and HS13-194 (E. faecium) were used as controls for the respective groups.
17 versus 102, 55 versus 102, 17 + LZD versus 17, 55 + LZD versus 55, 202 versus ATCC29213, 202 + LZD versus 202, 304 versus ATCC29212, 309 versus
ATCC29212, 309 + LZD versus HS12-309 showed significantly differences (**P≤ 0.001; ***P < 0.0001, two-tailed t-test).
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http://www.biomedcentral.com/1471-2180/14/292above, cfr flanked by two IS256-like elements may be trans-
mitted from animal-derived isolates to human-derived
isolates and spread horizontally within, or even between,
bacterial species. Therefore, ongoing surveillance is essen-
tial to avoid the dissemination of linezolid resistance.
Mutations in ribosomal proteins L3, L4 and L22 of the
peptidyltransferase centre also contribute to decreased
susceptibility to linezolid [7,12-14]. In our study, mutation
C316T (Arg106Cys) in L4 was first detected in two S.
capitis clones (HS12-201, HS12-55) and mutation C389G
(Ala130Gly) in L3 was first detected in S. aureus (HS11-
202). None of the LR isolates contained mutations in L22.
Because no other mutation was detected in S. aureus
HS11-202, which has a linezolid MIC of 16 μg/ml, sug-
gesting that the Ala130Gly mutation in L3 might be as-
sociated with low-level linezolid resistance.
Biofilm could provide a microenvironment for bacteria
to survive. Bacteria in a biofilm aggregated into micelles
which could withstand attacks by innate host defence
mechanisms and evaded the threats of antibiotics [15].We performed a semi-quantitative biofilm assay, which
only showed that biofilm formation was significantly higher
in LR E. faecalis isolates than in LS E. faecalis isolates. This
suggested that formation of biofilm might increase low-level
resistance to linezolid in LR E. faecalis (MICs 4–8 μg/ml).
We performed TEM to determine whether the decreased
susceptibility of LI and/or LR strains was related to the
thickness of the cell wall. We found that the cell walls of LI
and LR strains were significantly thicker than LS strains.
Also, the cell walls of LR strains grown with linezolid were
thicker than those of LR strains grown without linezolid.
These thicked cell wall bacteria were probably selected by
the linezolid pressure and might be able to avoid clearance
in patients undergoing antibiotic therapy. There was no
significant differences in cell wall thickness between LI and
LR strains. Data suggested that the thickness of the cell
wall might decrease susceptibility to linezolid to a cer-
tain degree, but not play a major role in linezolid resist-
ance. Furthermore, no significant differences in cell wall
thickness were observed between LS HS13-194 and LI
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http://www.biomedcentral.com/1471-2180/14/292HS11-306 E. faecium isolates, however, we observed a
thick transparent substance around the bacteria. Whether
this substance might hinder linezolid absorption and
result in resistance is unknown.
Conclusion
In summary, various levels of LR strains have emerged in
Shanghai, China in our study. Mutiple resistance mechan-
ism were involved in these LR strains. Although the preva-
lence of resistance to linezolid remains low, the emergence
of LR staphylococcal and enterococcal clinical isolates
should prompt increased attention, especially for the hori-
zontal dissemination of cfr, and surveillance of linezolid
resistance in Gram-positive bacteria is of increasing
importance.
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